Karolinska Development

Activities: Research & Development Finance Pharmaceutical

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Interphex

16-18 April 2024 | Conference and Exhibition | New York, US See all

Related Content

Recruitment

Karolinska Development appoints Fredrik Jarrsten as Chief Financial Officer

Mr Järrsten will join the company towards the end of 2017

Karolinska changes Chair and CEO

Karolinska Development announces Chair Bo Jesper Hansen and CEO Jim Van heusden’s decision to step down
Finance

Karolinska Development portfolio company Promimic AB appoints Magnus Larsson as new CEO and launches US sales operation

Karolinska Development AB has announced that its portfolio company Promimic AB, an innovative biomaterials company developing and commercialising medical implant technologies that enhance bone healing, has announced the appointment of Magnus Larsson as Chief Executive Officer.
Regulatory

Karolinska Development portfolio company Dilafor AB granted U.S. patent for Phase II drug tafoxiparin

Karolinska Development AD has announced that its portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has been granted a U.S. patent protecting its proprietary compound tafoxiparin.
Research & Development

Recipharm invests SEK8m in Pharmanest

To support the development of Pharmanest’s leading drug candidate SHACT
Finance

Karolinska Development invests in Forendo Pharma

Finland-based firm is developing treatments for endometriosis and for low testosterone levels
Subscribe now